{"id":"NCT02435173","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Efficacy of CDZ173 in Patients With APDS/PASLI","officialTitle":"An Open-label, Non-randomized, Within-patient Dose-finding Study Followed by a Randomized, Subject, Investigator and Sponsor Blinded Placebo Controlled Study to Assess the Efficacy and Safety of CDZ173 (Leniolisib) in Patients With APDS/PASLI (Activated Phosphoinositide 3-kinase Delta Syndrome/ p110δ-activating Mutation Causing Senescent T Cells, Lymphadenopathy and Immunodeficiency)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2015-08-24","primaryCompletion":"2021-08-16","completion":"2021-08-16","firstPosted":"2015-05-06","resultsPosted":"2022-03-11","lastUpdate":"2022-08-10"},"enrollment":37,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Common Variable Immunodeficiency (CVID), APDS / PASLI"],"interventions":[{"type":"DRUG","name":"CDZ173","otherNames":["Leniolisib"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Part I: CDZ173","type":"EXPERIMENTAL"},{"label":"Part II: CDZ173","type":"EXPERIMENTAL"},{"label":"Part II: Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study was designed to explore CDZ173, a selective PI3Kδ inhibitor, in patients with genetically activated PI3Kδ, i.e., patients with Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency (APDS/PASLI).\n\nThe study consisted of two parts: Part I was the open label part designed to establish the safety and pharmacokinetics of CDZ173 in the target population, as well as to select the optimal dose to be tested in Part II. Part II was designed to assess efficacy and safety of CDZ173 in the target population.","primaryOutcome":{"measure":"Part I: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"From the start of treatment to 30 days after end of treatment, assessed up to maximum duration of 114 days","effectByArm":[{"arm":"Part I: CDZ173 10 mg","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":10,"countries":["United States","Belarus","Czechia","Germany","Ireland","Italy","Netherlands","Russia","United Kingdom"]},"refs":{"pmids":["36399712","28972011"],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=1058","https://www.novctrd.com/ctrdweb/ppatientsummary/ppatientsummaries?periodicPatientSummaryId=527"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":6},"commonTop":["Headache","Sinusitis","Diarrhoea","Nausea","Upper respiratory tract infection"]}}